Charcoal-Based Hemodiabsorption Liver Support for Episodic Type C Hepatic Encephalopathy

American Journal of Gastroenterology

Volumn 98, Issue 12, 2003, Pages 2763-2770

  Hill, Kevin ^a   Hu, Ke Qin ^a   Cottrell, Alfred ^a   Teichman, Sigmund ^a   Hillebrand, Donald J ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHARCOAL; HEPARIN;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; HEMADSORPTION; HEPATIC ENCEPHALOPATHY; HUMAN; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0346103744     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.08768.x     Document Type: Article

References (46)

1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification. Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-21.
2. Centers for Disease Control and Prevention. 10 leading causes of death, United States, 1990-1998. [NCHS vital statistics system for number of deaths: Bureau of Census for Population Estimates. Statistics compiled by the office of statistics and programming, NCIPC, CDC]. Atlanta, GA Center for Disease Control, 1999.
3. Health Care Investment Analysts. 1998 HCIA's hospital patient profile (October 1, 1997-September 30, 1998) data summary. Available at: www.hcia.com/products/hpp.
4. Kamath PS, Wiessner RH, Malinchoc M, et al. A model to predict survival in patients with end stage liver disease. Hepatology 2001;33:464-70.
5. Morgan MY, Hawley KE. Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients. A double-blind, randomized trial. Hepatology 1987;7:1278-84.
6. Orlandi F, Freddara U, Candelasresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy. A randomized clinical study. Dig Dis Sci 1981;26:498-506.
7. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 1992;16:138-44.
8. Rossi-Fanelli F, Riggio O, Cangiano C, et al. Branched-chain amino acids vs lactulose in the treatment of hepatic coma. A controlled study. Dig Dis Sci 1982;27:929-35.
9. Blanc P, Daures JP, Liatuard J, et al. Association lactuloseneomycine versus placebo dans le traitement de l'encephalopathie hepatique aiguel. Resulats d'un essai controle randomise. [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial.] Gastroenterol Clin Biol 1994;18:1063-68.
10. Blei AT, Cordoba J. Hepatic encephalopathy practice guidelines. Am J Gastroenterol 2001;96:1968-76.
11. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-5.
12. Atterbury CE, Maddrey WC, Conn HO. Neomycin, sorbitol and lactulose in the treatment of acute portal systemic encephalopathy: A controlled double blind clinical trial. Am J Dig Dis 1978;23:398-406.
13. Conn HO, Lieberthal MM. The syndrome of portal systemic encephalopathy. In: Conn HO, Lieberthal MM, eds. The hepatic coma syndrome and lactulose. Baltimore. Williams & Wilkins, 1978;1-45.
14. Strauss E, Tramote R, Silva EPS, et al. Double randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
15. Morgan M, Read AE, Speller PCE. Treatment of hepatic encephalopathy with flagyl. Gut 1982;23:1-7.
16. Ferenci P, Grimm G, Meryn S, et al. Successful long-term treatment of portal systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 1989;96:240-3.
17. Hui J, Rozga J, Demetrion AA. Bioartificial liver support. J Hepatobiliary Pancreat Surg 2000;8:1-15.
18. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999;5:29-34.
19. Kramer L, Gendo A, Madl C, et al. Biocompatibility of a cuprophane charcoal based detoxification device on cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 2000;36:1193-200.
20. Nyberg SL, Misra SP. Hepatocyte liver assist systems - a clinical update. Mayo Clinic Proc 1998;73:765-71.
21. Kiley JE, Pender JC. Treatment of hepatic coma by hemodialysis. Trans Am Soc Artif Intern Organs 1957;3:86-8.
22. Kiley JE, Awelch HF, Pender JC. Removal of blood ammonia by hemodialysis. Proc Soc Rxp Biol Med 1958;91:489-90.
23. O'Grady JG, Gimson AES, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988:94:1186-92.
24. Ash SR. Hemodiabsorption in treatment of acute hepatic failure and chronic cirrhosis with ascites. Artif Organs 1994;18:355-62.
25. Ellis AJ, Hughes RD, Nicholl D, et al. Temporary liver support for severe acute alcoholic hepatitis using the BioLogic-DT. Intern J Artif Organs 1999;22:27-34.
26. Ash SR. Powdered sorbent liver dialysis and pheresis in treatment of hepatic failure. Ther Apher 2001;5:404-16.
27. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review. JAMA 2003;289:217-22.
28. Ash SR, Blake DE, Carr DJ, et al. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (The BioLogic-DT). Intern J Artific Organs 1992;15:151-61.
29. Mitzner SR, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent Recirculating System for critically ill patients with liver failure. J Am Soc Nephrol 2001;12:S75-82.
30. Conn HO. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Dig Dis 1977;22:541-50.
31. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-9.
32. Bull BS, Huse WM, Brauer FS, et al. Heparin therapy during extracorporeal circulation. J Thorac Cardiovasc Surg 1975;69:685-89.
33. Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study. Hepatology 1994;20:46-55.
34. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portosystemic encephalopathy. Gastroenterology 1977;72:573-83.
35. Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan battery: Demographic corrections, research findings and clinical applications. Odessa, TX: Psychological Assessments Resources, 1991.
36. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy. Metabolic consequences of cirrhosis often is reversible. Postgrad Med 2001;109:57-60.
37. Atterbuty CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: A controlled, double-blind clinical trial. Dig Dis 1978;23:398-406.
38. Heredia D, Caballeria J, Arroyo V. et al. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial. J Hepatol 1987;4:293-8.
39. Pai CH, Huang YS, Jeng WC, et al. Treatment of porto-systemic encephalopathy with lactitol versus lactulose: A randomized controlled study. Chin Med J 1995;55:31-6.
40. Strauss E, Costa MF. The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 1998;45:900-4.
41. Hughes RD, Pucknell A, Routley D, et al. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Intern J Artif Organs 1994;17:657-62.
42. Ash SR, Steczko J, Knab WR, et al. Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: Preliminary results of a clinical trial with the BioLogic-DTPF system. Ther Apher 2000;4:218-28.
43. Langley PG, Keays R, Hughes RD, et al. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 1991;14:251-56.
44. Basili S, Merli M, Ferro D, et al. Clotting activation after transjugular intrahepatic portosystemic stent shunt. Thromb Haemost 1999;81:711-4.
45. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. J Thorac Cardiovasc Surg 1975;69:674-84.
46. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975;43:346-53.